Future Trends in Refractive Surgery

Next-Gen LVC - Laser Sharp Futures

• Femtosecond Laser Advancements:
  • Higher frequency (> 1 MHz), lower energy systems: Smoother cuts, reduced inflammation, faster recovery.
  • Robotic assistance: Enhanced precision, improved docking, and surgical consistency.
• Novel Ablation Profiles & Techniques:
  • SILK (Smooth Incision Lenticule Keratomileusis): Advanced lenticule extraction.
  • CAIRS (Corneal Allogenic Intrastromal Ring Segments): For keratoconus management.
  • Sophisticated topography-guided ablations & presbyopia-correcting profiles (e.g., PresbyMAX).
• AI Integration in LVC:
  • Pre-op: AI-driven personalized nomograms, advanced risk stratification.
  • Intra-op: AI for real-time eye tracking, cyclotorsion compensation.
  • Post-op: AI for predictive modeling of outcomes.

⭐ SILK (Smooth Incision Lenticule Keratomileusis) by J&J Vision aims for improved outcomes by creating biconvex lenticules and smoother stromal beds, potentially offering quicker visual recovery.

Advanced Lens Solutions - Intelligent Lens Innovations

• Extended Depth of Focus (EDOF) IOLs:
  • Provide a continuous range of vision, reducing spectacle dependence.
  • Work by creating a single elongated focal point, unlike multifocal distinct points.
  • May have fewer halos/glare issues compared to older multifocal IOLs.
• Trifocal IOLs:
  • Offer clear vision at near, intermediate, and distant focal points.
  • Aim to provide greater spectacle independence.
• Accommodating IOLs (AIOLs):
  • Designed to mimic the eye's natural accommodation by changing focus.
  • Mechanisms: axial movement, shape change, or refractive index shift.
  • Current generation offers limited but improving accommodative amplitude.
• Phakic IOLs Evolution:
  • Improved materials (e.g., collamer) and designs (e.g., central port for aqueous flow - reduces cataract/glaucoma risk).
  • Wider range of dioptric correction.
• Minimally Invasive Techniques:
  • Preloaded IOL injectors for smaller incisions.
  • Femtosecond laser-assisted lens surgery for precision.

⭐ Light Adjustable Lens (LAL): Allows non-invasive, post-operative refinement of sphere, cylinder, and EDOF profile using UV light, offering precise visual outcomes. This is a significant advancement in customizable vision correction after cataract surgery or refractive lens exchange (RLE).

Corneal Biomechanics & Regeneration - Cornea's Comeback Crew

• Corneal Biomechanics: Assesses corneal strength (CH, CRF); vital for ectasia risk.
• Advanced Cross-Linking (CXL): Halts ectasia. Standard (Dresden): 3 $mW/cm^2$, 30min.
  • Epi-on CXL: Transepithelial, ↓pain, faster recovery.
  • Accelerated CXL: ↑UVA (e.g., 9 $mW/cm^2$, 10min), ↓duration.
  • CXL Xtra/Plus: CXL with PRK/ICRS.
• Expanded CXL Horizons:
  • Thin Corneas (<400 $\mu m$): With hypo-osmolar riboflavin.
  • Infectious Keratitis (IK): Pack-CXL as adjunct therapy.
• Corneal Regeneration:
  • Endothelial Cell Therapy: Cultured cells for endothelial dysfunction.
  • Bioengineered Corneas: Stromal analogues, 3D bioprinting.
  • Lenticule Re-implantation: SMILE lenticules for hyperopia/aphakia. 📌 ReLACS

⭐ Corneal Allogenic Intrastromal Ring Segments (CAIRS) using donor cornea are emerging for keratoconus, offering better biocompatibility than synthetic ICRS.

Pharmacological & Novel Approaches - Drug & Gene Dreams

• Presbyopia Eye Drops:
  • Miotics (e.g., Pilocarpine HCl 1.25% - Vuity): ↑ depth of focus via miosis.
  • Lens softening agents (experimental): Aim to restore accommodation.
• Pharmacological Myopia Control:
  • Low-dose Atropine (0.01% - 0.05%): Most effective, slows progression. Mechanism: non-accommodative, acts on scleral/retinal receptors.
  • Pirenzepine (M1 antagonist), 7-Methylxanthine (adenosine antagonist) - less common.
• Gene Therapy (Investigational):
  • Targets: Scleral remodeling genes (e.g., collagen, MMPs), growth factors (e.g., TGF-β).
  • Goal: Modulate eye growth, scleral biomechanics to prevent/correct myopia.
  • Vectors: Adeno-Associated Virus (AAV) commonly explored.

⭐ Low-dose atropine (0.01%) is a widely recognized pharmacological intervention for effectively slowing myopia progression in children, with minimal side effects compared to higher concentrations.

High‑Yield Points - ⚡ Biggest Takeaways

• Lenticule extraction advancements like SMILE Pro & CLEAR promise faster, wider applications.
• Highly personalized ablations using topography-guided & wavefront-optimized techniques are increasing.
• Novel presbyopia solutions include advanced corneal inlays, presbyLASIK, and scleral procedures.
• Light Adjustable IOLs (LAL) offer precise, non-invasive post-operative refractive adjustment.
• Pharmacological myopia control (e.g., low-dose atropine) and CXL alternatives are key research areas.
• Artificial Intelligence (AI) is enhancing patient selection, surgical planning, and outcome prediction.